Allianz Asset Management’s AnaptysBio ANAB Stock Holding History

Allianz Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15,200	Closed	-$337K	–	1998
2025 Q2	$337K	Buy	+15,200	New	+$318K	﹤0.01%	1894
2020 Q1	–	Sell	-13,630	Closed	-$221K	–	2462
2019 Q4	$221K	Sell	13,630 -156	-1%	-$3.69K	﹤0.01%	2644
2019 Q3	$483K	Sell	13,786 -10,273	-43%	-$489K	﹤0.01%	2384
2019 Q2	$1.36M	Sell	24,059 -1,714	-7%	-$123K	﹤0.01%	2030
2019 Q1	$1.88M	Buy	25,773 +17,307	+204%	+$1.19M	﹤0.01%	1859
2018 Q4	$540K	Buy	+8,466	New	+$630K	﹤0.01%	2243

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Allianz Asset Management's ANAB Position: Q3 2025 in Review

Allianz Asset Management sold out of AnaptysBio (ANAB) in Q3 2025, closing a stake of 15,200 shares — an estimated $337K sold.

Allianz Asset Management first reported a position in ANAB in Q4 2018 and held it in 6 quarters. The position peaked at $1.88M in Q1 2019. 166 funds tracked by Wall St. Rank hold ANAB as of Q3 2025.

Allianz Asset Management reported no remaining AnaptysBio position as of Q3 2025 after selling out during the quarter.
Allianz Asset Management sold 15,200 AnaptysBio shares in Q3 2025, an estimated $337K.
Allianz Asset Management first reported a position in AnaptysBio in Q4 2018 and held it in 6 quarters.
Allianz Asset Management's AnaptysBio position peaked at $1.88M in Q1 2019.
166 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2025.

Based on Allianz Asset Management's 13F filing for Q3 2025, filed 4 Nov 2025.